Breakthrough Wilson's Disease Treatment Reverses Brain, Liver, and Kidney Damage in Preclinical Study

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

Treatment reversed tremors, ataxia, anxiety-like behavior, liver and kidney pathology damage, reduced copper accumulation, normalized ALT, AST, and bilirubin levels, and improved survival.

Telomir Pharmaceuticals Announces Preclinical Success with Telomir-1 in Wilson’s Disease Model

Telomir Pharmaceuticals, a preclinical stage pharmaceutical company, has recently unveiled promising preclinical data for its lead candidate, Telomir-1, in the treatment of Wilson’s disease. This rare disorder, characterized by excessive copper accumulation in the body, has seen potential therapeutic advancements through Telomir-1’s ability to significantly reverse neurological, liver, and kidney symptoms in a genetic animal model. In studies co…

Breakthrough Wilson's Disease Treatment Reverses Brain, Liver, and Kidney Damage in Preclinical Study

New data reveals Telomir-1 reduces tremors 5-fold and copper buildup 50% in Wilson's disease model, while reversing organ damage. See complete trial results.